Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Natl Cancer Inst
Prif Awduron: Brastianos, Priscilla K., Shankar, Ganesh M., Gill, Corey M., Taylor-Weiner, Amaro, Nayyar, Naema, Panka, David J., Sullivan, Ryan J., Frederick, Dennie T., Abedalthagafi, Malak, Jones, Pamela S., Dunn, Ian F., Nahed, Brian V., Romero, Javier M., Louis, David N., Getz, Gad, Cahill, Daniel P., Santagata, Sandro, Curry, William T., Barker, Fred G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2015
Pynciau:
Brief Communication
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4862417/
https://ncbi.nlm.nih.gov/pubmed/26498373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djv310
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg